Skip to main content
Download PDF

Beneficial effects of GABA-producing potential probiotic Limosilactobacillus fermentum L18 of human origin on intestinal permeability and human gut microbiota

Microbial Cell Factories volume 22, Article number: 256 (2023) Cite this article

Abstract

Background

Gamma-aminobutyric acid (GABA) is a non-protein amino acid with neuroinhibitory, antidiabetic, and antihypertensive properties and is used as a drug for treating anxiety and depression. Some strains of lactobacilli are known to produce GABA and strengthen the gut barrier function which play an important role in ameliorating the effects caused by the pathogen on the gut barrier. The probiotic bacteria are also known to modulate the human fecal microbiota, however, the role of GABA-producing strains on the gut epithelium permeability and gut microbiota is not known.

Results

In this study, we report the production of high levels of GABA by potential probiotic bacterium Limosilactobacillus fermentum L18 for the first time. The kinetics of the production of GABA by L18 showed that the maximum production of GABA in the culture supernatant (CS) occurred at 24 h, whereas in fermented milk it took 48 h of fermentation. The effect of L18 on the restoration of lipopolysaccharide (LPS)-disrupted intestinal cell membrane permeability in Caco-2 monolayers showed that it significantly restored the transepithelial electrical resistance (TEER) values, by significantly increasing the levels of junction proteins, occludin and E-cadherin in L18 and LPS-treated Caco-2 cells as compared to only LPS-treated cells. The effect of GABA-secreting L18 on the metataxonome of human stool samples from healthy individuals was investigated by a batch fermentor that mimics the conditions of the human colon. Although, no differences were observed in the α and β diversities of the L18-treated and untreated samples at 24 h, the relative abundances of bacterial families Lactobacillaceae and Bifidobacteriaceae increased in the L18-treated group, but both decreased in the untreated groups. On the other hand, the relative abundance of Enterobacteriaceae decreased in the L18 samples but it increased in the untreated samples.

Conclusion

These results indicate that Li. fermentum L18 is a promising GABA-secreting strain that strengthens the gut epithelial barrier by increasing junction protein concentrations and positively modulating the gut microbiota. It has the potential to be used as a psychobiotic or for the production of functional foods for the management of anxiety-related illnesses.

Background

Human intestinal microbiota is considered an “organ” of the gastrointestinal tract that plays important roles in the host’s digestive process, epithelial cell development, and regulation of immunity, thereby contributing to the overall health of the host. An imbalance in the normal gut microbiota, known as dysbiosis, has been linked to number of inflammatory gut-associated diseases and metabolic illnesses [1]. Several studies have shown that the dysbiotic condition of the gut can be treated by using various therapeutic strategies such as intake of probiotics [2], prebiotics [3] and fecal transplantation of microbiota [4]. Probiotics are ‘live microorganisms that when administered in adequate amounts confer a health benefit on the host’ [5]. Probiotic bacteria belonging to the group lactic acid bacteria (LAB) such as Limosilactobacillus reuteri [6], Lactiplantibacillus plantarum, Lactococcus lactis and Lactobacillus delbrueckii [7] have been successfully used for the management and treatment of dysbiosis-related illnesses due to their ability to modulate the microbiota of the gut. Other benefits imparted by probiotic bacteria to the host include colonization resistance against pathogens and strengthening of the tight junction barrier of the gut epithelium [8]. Alteration of the diversity of the microbiome is associated with altered expression of junction proteins that further changes the permeability of the gut epithelial membrane [9]. Disruption of gut epithelial barrier is associated with the pathogenesis of lifestyle-related diseases such as diabetes [10], Crohn's disease [11, 12] and coeliac disease [13, 14]. Enteric pathogens disrupt the epithelial barrier either by causing alterations in the cytoskeleton or by the production of enzymes such as proteases that degrade tight junction proteins [15]. Whereas, probiotic bacteria are known to restore the gut epithelial barrier by inhibiting the growth of pathogens and by directly impacting the tight junction proteins of the epithelium.

Probiotic bacteria also benefit the host by secreting bioactive molecules. For example, some strains of lactobacilli have been shown to secrete essential amino acids [16], short-chain fatty acids [17], γ-aminobutyric acid [18] and exopolysaccharides [19] that play essential roles in the metabolism of a healthy host [20]. GABA is a non-protein amino acid that is produced in the human colon by gut microbiota due to the decarboxylation reaction carried out by the enzyme glutamate decarboxylase. GABA is one of the major inhibitory neurotransmitters in the mammalian central and peripheral nervous systems. Its oral intake has various beneficial effects including tranquilizing, hypotensive, diuretic and anti-diabetic [21]. Deficiency of GABA leads to neuropsychiatric disorders such as anxiety and depression. Therefore, extensive studies are being conducted to develop GABA-rich food supplements [22] that leverage manifold health benefits [23] such as neurostimulation [24], gut modulation [25] and cardioprotection [26]. Hagiwara et al. [27] demonstrated that GABA promotes the secretion of insulin from the pancreas, thereby preventing diabetes. GABA consumption can also regulate stress [28] and serum lipid levels [29]. Schuller et al. [30] demonstrated that GABA inhibits small airway-derived lung adenocarcinoma in mouse models. GABA production by Lacti. plantarum [31, 32], L. brevis [33], Lacticaseibacillus paracasei [34], Lentilactobacillus hilgardii [35] and Len. buchneri [36] have been reported. Pharma-GABA approved by the Food and Drug Administration (FDA) as a food ingredient [37] is produced by fermentation process using Len. hilgardii K-3 [35]. The effect of GABA-producing lactobacilli strains on the gut microbiota and gut epithelium is not known.

In our previous study [38], the probiotic properties and safety aspects of lactobacilli strains isolated from the stool samples of healthy children was studied. The cell-free culture supernatant (CS) of L18 exhibited antibiofilm properties against Vibrio cholerae and V. parahaemolyticus. In this study, the GABA-producing potential of the isolated lactobacilli was compared. Further, the effects of Li. fermentum L18 on the permeability of colonic epithelial cell membrane and the modulatory effects of L18 supplementation on the metataxonome of the human fecal microbiome in batch fermentation was studied.

Materials and methods

Microorganisms and growth conditions

Li. fermentum L18 and other 7 lactobacilli were isolated and characterized (Additional file 1: Table S1) from the fecal samples of healthy children in the lab of Dr. Sukhraj Kaur in a previous study [38]. Lactobacilli were cultured in de Man Rogosa Sharpe (MRS; HiMedia Pvt. Laboratory, Mumbai, India) medium at 37 °C in anaerobic gas jars or in an anaerobic cabinet in an atmosphere of 5% CO2, 10% H2 and 85% N2 (Don Whitley, UK). The culture was preserved in 20% glycerol-containing MRS broth at − 80 °C and subcultured twice in MRS broth before using for the experiments. Log phase cultures were used for all the experiments.

Cell lines and culture conditions

Human epithelial colorectal adenocarcinoma Caco-2 cell line was gifted by Dr. Sandra Tribola, Quadram Institute Biosciences (QIB), Norwich, United Kingdom. Caco-2 was cultured in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich Chemicals Pvt. Limited, St. Louis, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich) at 37 °C in 5% CO2-containing atmosphere. The media was changed regularly every 2 days. The Caco-2 cells with passage number 15 was used for the experiments.

Upon attaining > 80% confluency, the cells were harvested by trypsinization. For trypsinization, the adhered cells were washed twice with phosphate-buffered saline (PBS; pH 7) and 5 ml of 0.25% trypsin–EDTA solution (Sigma-Aldrich) was added to the cells and incubated at 37 °C for 5 min. The action of trypsin was stopped by the addition of 5 ml of medium. The trypsinized cells were collected in a sterile centrifuge tube and centrifuged at 200 g for 5 min at 37 °C. The pellet was suspended in 1 ml of medium and the cells were counted using trypan blue staining [39].

Estimation of GABA

The production of GABA in CS by L18 was determined by an amino acid analyzer (Nexera X2, Shimadzu Asia Pacific Ltd, Japan). L18 was cultured in MRS broth containing 2% monosodium glutamate (MSG; HiMedia). To prepare the CS, lactobacilli were cultured for 16 h at 37 °C and the broth was centrifuged at 9000g for 10 min at 4 °C. The supernatant was then filter sterilized using syringe filters (0.2 μm) and stored at 4 °C until further use.

To study the production kinetics of GABA, CS was collected at different time points (24 h, 48 h and 72 h) and stored at 4 °C till further use. One microlitre of filter-sterilized CS was injected into the amino acid analyzer column, C18 (YMC-Triart, India), and detection was performed using fluorescent detector (RF-20A).

The production of GABA was also studied in 2% MSG-containing milk. The overnight grown culture of L18 was inoculated at 2% in 10% skim milk powder (HiMedia) containing 2% MSG and incubated for 48 h at 37 °C in anaerobic jars. After incubation, the fermented milk was treated with an equal volume of 24% trichloroacetic acid (HiMedia) and filtered through Whatmann 3 mm filter paper. The coagulated proteins were discarded and GABA levels in the filtrate were determined using the amino acid analyzer.

Effect of lactobacilli on integrity of the epithelial cell barrier

The protective effect of L18 on the restoration of the integrity of LPS-disrupted confluency of colonic cell line Caco-2 cell monolayers was determined in vitro [40]. Caco-2 cells were seeded in the inserts of 24–transwell plates (Greiner Bio-One Ltd, United Kingdom) at the cell density of 0.33 × 105 cells/cm2 in DMEM and incubated at 37 °C in 5% CO2-containing atmosphere. The media was changed on alternate days and the integrity of the monolayers was determined by measuring TEER of monolayers using a Millicell Electrical Resistance System (Millipore, Billerica, USA). The cell line was considered to be confluent after the TEER > 1000 Ω × cm2 was achieved. The cells were allowed to differentiate until day 14 and thereafter, the integrity of monolayers was disrupted by treating with 0.1 mg/ml LPS (Sigma-Aldrich). The integrity of the cell line in terms of TEER values was monitored after every 2 h. After 48 h of LPS treatment, L18 at concentration 107 cells/ml was added to the apical wells and DMEM media without antibiotic was added to the basal wells. TEER values of the Caco-2 cells in different wells were measured up to 8 h.

Effect of L18 on junction proteins of Caco-2 cells

The effect of L18 on the junction proteins of Caco-2 cells, occludin and E-cadherin was estimated by ELISA. After 4 h of the addition of L18 to the Caco-2 cells, trypsinization of the cells was performed and the collected cells were lysed by incubating the cells with chilled lysis buffer (0.2% triton-X prepared in 1X PBS, pH 7.2) for 5 min on ice followed by vortexing for 10 s. The lysed cells were centrifuged at 5000g for 20 min at 4 °C. The supernatant was collected and stored at − 20 °C till further use.

The levels of occludin protein and E-cadherin protein in the cell lysate of Caco-2 cells were determined using a Sandwich human occludin ELISA kit (Abbexa Ltd., Cambridge Science Park, Cambridge) and human E-cadherin ELISA kit (Invitrogen, Thermo Fisher Scientific Inc., USA), respectively as per the protocol of the manufacturer.

Batch fermentation of fecal sample and analysis of microbiome composition

The modulatory effect of L18 on the human fecal microbiota was studied in a batch fermentation model [41, 42]. The in vitro batch fermentation was carried out for 24 h with continuous pH control 6.8 ± 2 of the set value in different vessels used to mimic the human colon. Fecal samples used in the colon model experiments were obtained from participants recruited in the QIB Colon Model study. Participants who were assessed to have normal bowel habits, regular defecation between three times a day and three times a week, with an average stool type of 3–5 on the Bristol Stool Chart, and no diagnosed chronic gastrointestinal health problems, such as irritable bowel syndrome, inflammatory bowel disease, or coeliac disease were enrolled onto the study. Demographic information was collected, and a brief health questionnaire was completed during the eligibility screening. Participants were asked additional questions immediately before donating a stool sample to confirm that they had not taken antibiotics or probiotics within the last four weeks, had not experienced a gastrointestinal complaint, such as vomiting or diarrhea, within the last 72 h, were not currently pregnant or breast-feeding, had not recently had an operation requiring general anesthetic, and were not taking iron or multivitamin supplements. The informed consent of all the participating subjects was obtained. The study was approved by the UK research ethics committee (REC15/LO/2169). Batch fermentation of feces was initiated by using prepared fecal inoculum that was processed by taking 10 g of fresh fecal samples from healthy volunteers and diluting 10 times in deoxygenated PBS (pH 7.7). The diluted feces were homogenized by using a Stomacher 400 (Seward, United Kingdom) operated at 230 rpm for 45 s. The overnight grown culture of Li. fermentum L18 in MRS broth was added to the vessel containing 135 ml of batch culture media (peptone water 2 g/l, yeast extract 2 g/l, NaCl 0.10 g/l, K2HPO4 0.04 g/l, KH2PO4 0.04 g/l, MgSO4.7H2O 0.01 g/l, CaCl2.2H2O 0.01 g/l, NaHCO3 2 g/l, Tween 80 2 ml, glucose 10 g/l, vitamin K1 10 μl, cysteine HCl 0.5 g/l, bile salts 0.5 g/l, pH 7.0) at the final concentration of 2 × 106 cells along with 15 ml of the processed fecal inoculum. At different time points (0, 8, 24 h), 13 ml samples were withdrawn and 1 ml of sample was used for colony-forming units (CFU) counting and remaining 12 ml sample were centrifuged at 3000g for 15 min and pellets were stored at − 20 °C. For CFU counting, samples were serially diluted in PBS inside the anaerobic cabinet. The total number of bacteria and the number of Bacteroides, Bifidobacterium, Clostridium, Lactobacilli, and Enterobacter spp. in each vessel were estimated by total CFU counts using Wilkins Chalgren, Bacteroides, Beerens, Clostridia, MRS, and McConkey selective agar plates, respectively (Oxoid, Basingstoke, Hampshire, UK). The samples were centrifuged at 3000g for 15 min and the pellets were stored at -20 °C for metataxonomic studies. Batch cultures were performed on three occasions.

Metataxonomic profiling by 16S rRNA gene amplicon sequencing

To determine the bacterial composition of the fecal batch fermentation samples, paired-end 250 bp amplicon sequencing was carried out on an Illumina MiSeq instrument. The DNA from one of the fecal batch fermentation samples collected at different time points 0, 8, and 24 h was extracted by using FastDNA SPIN Kit (MP Biomedicals, California, USA).

The V4 region of the 16S rRNA gene was amplified with primers: 515F:5′-GTGCCAGCMGCCGCGGTAA-3′ and 806R: 5′-GGACTACHVGGGTWTCTAAT-3′ (Caporaso et al. 2012). The bar-coded 6-base ID tags were attached to both forward and reverse primers and were used to demultiplex samples. Sequence analysis was performed using the Quantitative Insights into Microbial Ecology (QIIME2 v.2018.8) pipeline [43]. Quality control and clustering of sequence variants were carried out using DADA2 [44]. Taxonomic assignment of the clusters was carried out using a naïve Bayes classifier pre-trained on the SILVA 132 rRNA database. Weighted UniFrac distances as well as observed operational taxonomic units (OTU) were determined to estimate beta and alpha diversity, respectively. Two-dimensional Principal coordinate analysis (PCoA) plots were generated with the Microsoft Excel plug-in XLSTAT using the weighted UniFrac distance matrix produced by QIIME2. Differential abundance testing between treatments/timepoints at the family level was performed using ANCOM [45].

Statistical analysis

All the experiments were performed in triplicates and results shown are from three independent experiments represented as mean ± SD (standard deviation). The results were statistically analysed using unpaired Student’s t-test in GraphPad Prism 5.04 software.

Results

GABA production by Li. fermentum L18

GABA-producing probiotic bacteria can serve as safe microbial source of GABA, that can be used to meet the increasing demands of GABA and GABA-enriched functional food. Lactobacilli isolated from healthy human stool samples were screened for the production of GABA in de Man Rogosa Sharpe (MRS) broth. Maximum production of GABA was observed in the CS fermented with for Li. plantarum L18 (Fig. 1A). The kinetics of GABA production by L18 was determined in MRS broth and milk samples. Li. fermentum L18 produced highest amounts of GABA (62.37 mg/ml) at 24 h, after which the concentration of GABA declined. At 72 h, the levels of GABA decreased to 24.45 mg/ml (Fig. 1B).

Fig. 1
figure 1

GABA production by A different Lactobacillus isolates in MSG (2%)-supplemented MRS (pH 5.5) and B Li. fermentum L18 MSG (2%)-supplemented MRS (pH 5.5) and in MSG-supplemented milk at different time points. The experiment was performed in triplicate. Bars are representative of the means and error bars represent the standard deviation

Full size image

However, in L18-fermented milk supplemented with 2% monosodium glutamate (MSG), maximum GABA production (49.78 mg/ml) was obtained at 48 h whereas, at 24 h and 72 h, the amount of GABA detected was 6.012 mg/ml and 20.32 mg/ml, respectively. Thus, L18 has the potential of producing GABA-enriched fermented milk products (Fig. 1B).

Effect of lactobacilli on the integrity of the epithelial cell barrier

The effect of viable cells of L18 on the restoration of LPS-induced disruption of the human epithelial cell barrier was determined by using a human colonic cell line, Caco-2. The integrity and tightness of epithelial monolayers can be measured by using a well-established method, wherein, the TEER is determined across the confluent cell line. The addition of 0.1 mg/ml of LPS to Caco-2 monolayers cultured in the apical chamber of transwell plates resulted in a time-dependent decrease in the TEER values thereby implying the disruption of the integrity of the monolayer (Fig. 2A). Within 2 h of the addition of LPS, the TEER value was reduced by 14% that further decreased by 25% after 48 h. On the other hand, the TEER values of the untreated control monolayers remained almost constant over a period of 48 h (Fig. 2A).

Fig. 2
figure 2

A TEER measurements of Caco-2 monolayers with and without treatment with LPS (0.1 mg/ml). B Percentage change in TEER values after addition of viable L18 cells to LPS-treated Caco-2 monolayers. The experiment was performed in triplicate. Significance of differences between untreated and LPS-treated was measured by using unpaired Student’s t-test. *Significance at p < 0.05

Full size image

After 48 h of the LPS treatment, viable L18 cells (2 × 106 colony forming units (CFU)/well) were added to the Caco-2 monolayers (Fig. 2B). Within 2 h of the addition of L18 isolate, TEER value was significantly (p < 0.05) restored above that of the untreated control and it peaked at 6 h. After 6 h, the TEER values started decreasing, probably because of the multiplication of lactobacilli.

Effect of lactobacilli on junction proteins

In order to study the mechanism of restoration of the integrity of Caco-2 cell line by L18, the concentrations of tight junction protein, occludin and adherens junction protein, E-cadherin in Caco-2 cell lysates exposed to LPS in the presence and absence of L18 was determined. LPS treatment of Caco-2 cells led to a 50% decrease in the levels of occludin (Fig. 3A) and E-cadherin (Fig. 3B) as compared to the untreated controls at 52 h. The addition of viable L18 cells to the LPS-stimulated Caco-2 monolayers resulted in a significant (p < 0.05) increase in the concentrations of occludin (Fig. 3A) and E-cadherin (Fig. 3B) within 4 h of the addition of L18. occludin levels were restored similar to that of the untreated controls (Fig. 3A) whereas, the levels of E-cadherin increased to 1.6 times that of untreated control (Fig. 3B).

Fig. 3
figure 3

Concentrations of A occludin protein and B E-cadherin protein in Caco-2 cell lysates either untreated, treated with LPS (0.1 mg/ml) or treated with LPS and then incubated with viable cells (2 × 106 CFU/well) of L18 isolate was determined by indirect Enzyme Linked Immunosorbent Assay (ELISA). The experiment was performed in triplicate. Bars are representative of the means and error bars represent standard deviation. Significant differences between the L18-treated sample and the only LPS-treated control were measured by using unpaired Student’s t-test. *Significance at p values < 0.05

Full size image

Batch fermentation of fecal sample and analysis of microbiota composition

The effect of the addition of Li. fermentum L18 on the composition of the fecal microbiota in a batch fermenter was determined by both standard plate counting method as well as 16S rRNA gene sequencing of stool samples after 0, 8 and 24 h of fermentation. Colony-forming units (CFU) counts obtained on various selective agar media showed that the addition of L18 resulted in significant (p < 0.05) increase in Bifidobacteria at 24 h as compared to the control group (Fig. 4B). On the other hand, significant (p < 0.05) reduction in Enterobacteriaceae was observed in L18-supplemented group as compared to control group (Fig. 4D). No significant differences were observed in the CFU count of Bacteroides (Fig. 4A) Lactobacilli (Fig. 4C), Clostridium (Fig. 4E) and total anaerobes (Fig. 4F) in both the groups.

Fig. 4
figure 4

Culturable bacterial numbers in pH-controlled batch cultures of stool samples after 24 h of fermentation in the presence and absence of Li. fermentum L18. A Bacteroides B Bifidobacteria C Lactobacilli, D Enterobacteriaceae E Clostridia F Total anaerobes. Bars are representative of the means of three experiments and error bars represent standard deviation. *Significance (p < 0.05) was measured by using unpaired Student’s t-test

Full size image

The metataxanome of the stool samples fermented in the presence or absence of L18 was evaluated at 0, 8 and 24 h and the data was compared. The sequence reads obtained per sample ranged from 193,274 to 309,057. After quality filtering, the sequence reads in range 159,453 to 250,226 were retained for further analysis. The operational taxonomic units (OTU) generated from the samples were in the range 345 to 557.

The alpha diversity of the samples at 0, 8 and 24 h was determined in terms of the Shannon index that takes into account species richness and evenness. The Shannon index decreased with time in both the groups but no differences were observed between the two groups (Fig. 5A).

Fig. 5
figure 5

Showing changes in microbiota composition in batch fermentation. A Shannon diversity index. B Principal coordinate analysis (PCoA) score plot based on weighted UniFrac distances. C Relative abundances of the four predominant phyla in the fermentation samples at 0 h and 24 h

Full size image

Further, PCoA analysis was performed to compare the microbial diversity at the phylum or family level between the two groups and at different time points. A PCoA score plot based on weighted UniFrac distances showed separate clustering of 8 h samples from the 0 h samples along the F1 axis (90.85% variability), thereby indicating decrease in diversity over time in both the L18-treated and the control groups (Fig. 5B). Controls and L18-treated samples at both the time points 8 and 24 h separated primarily along the F2 axis, that explains only 3.99% of the variability between the samples, therefore indicating that the addition of L18 has a less strong effect on the community composition than time.

The relative abundance of 4 predominant bacterial phyla was determined in the samples at 0 and 24 h. In the 0 h samples, Firmicutes predominated the fecal microbiota of both groups followed by Bacteroidetes, Proteobacteria, and Actinobacteria (Fig. 5C). After 24 h of fermentation, the relative abundance of Firmicutes and Bacteroidetes decreased and the levels of Proteobacteria increased in both samples. The increase in the Proteobacteria was 37.9% and 46.4% in the L18-treated group and untreated samples, respectively. The abundance of Firmicutes decreased in both groups by 30.2% and 35.7% in the L18-treated and untreated groups, respectively.

The relative abundances of 9 different bacterial families in the L18-treated and untreated control were compared (Fig. 6). An increase in the relative abundance of Lactobacillaceae was observed over time in the L18-treated group (from 3% at 0 h to 18.4% at 24 h) as compared to the untreated group where a decrease in the abundance was observed (from 2.3% at 0 h to 1.3% at 24 h). Similarly, an increase in the relative abundance of Bifidobacteriaceae from 1% at 0 h to 2% at 24 h in the L18-treated group was observed; whereas, its abundance decreased from 0.9% at 0 h to 0.3% at 24 h in the untreated control. On the other hand, the relative abundance of Enterococcaceae decreased from 5.9% (0 h) to 2.14% (24 h) whereas in untreated control an increase from 1% to 6.3% was observed. The relative abundance of Enterobacteriaceae increased in both the groups at 24 h but percentage increase in untreated control (46%) was higher as compared to L18-treated group (38%). The relative abundance of Clostridiaceae decreased in both groups. However, the decrease was more in the L18-treated group (3.8% at 0 h to 0.7% 24 h) as compared to the untreated group (2.9% at 0 h to 1% at 24 h). No notable differences were observed in the relative abundance of the rest of the other genera.

Fig. 6
figure 6

Relative abundance of different bacterial families in the samples obtained from fecal batch fermentations in the a L18-treated and b Untreated control group at 0, 8 and 24 h

Full size image

Discussion

Lactobacilli are one of the most frequently used probiotic groups due to their ‘Generally Regarded As Safe’ status. The health-promoting effects of lactobacilli is related to their ability to resist the colonization of pathogenic microbes due to the production of various beneficial metabolites such as organic acids, bacteriocins, etc. L18 is a potential probiotic bacterium that exhibited broad-spectrum, antimicrobial properties against both Gram-positive and Gram-negative bacteria owing to its ability to produce organic acids [38]. CS of L18 inhibited the biofilm formation of V. cholera and V. parahaemolyticus and caused the dispersion of preformed biofilms of Vibrio spp. The probiotic properties of L18 has already been reported in a previous study [38]. In this current study, we evaluated the ability of L18 to produce GABA and strengthen the intestinal epithelial barrier by enhancing the concentration of tight junction and adherens junction proteins.

The production of GABA by lactobacilli in medium supplemented with MSG has been reported earlier [46]. L. brevis is the most frequently reported species for GABA production. The highest production of 103.72 mg/ml of GABA in nutrient medium was reported from L. brevis NCL912 [47]. L. plantarum showed maximum levels of 0.20 mg/ml GABA in 3% MSG-supplemented MRS broth [32]. In another study, Li. fermentum produced 5.34 mg/ml of GABA in soya milk supplemented with 1.5% MSG. Thus, compared to these studies, L18 produced 10 times higher levels of GABA i.e., 62.37 mg/ml in MRS and 52 mg/ml in fermented milk. The levels of GABA decreased in CS by 2.3-fold after 72 h, which may be due to the action of the GABA-transaminase enzyme that reversibly converts GABA into succinic semialdehyde [48].

Further, the effect of L18 on the restoration of LPS-disrupted permeability of intestinal cell line was studied. The endotoxin LPS present in the cell wall of Gram-negative bacteria is known to increase epithelial permeability by disrupting the tight junction barrier [49]. Here we demonstrated that the addition of L18 to the LPS treated Caco-2 cell line resulted in improved tight junction barrier function after 2 h. However, after 6 h the reduction in TEER value was observed probably because of the overgrowth of bacteria. A study conducted by Fang et al. [50] showed that LPS treatment reduced the TEER of Caco-2 monolayers cocultured with peripheral blood mononuclear cells (PBMCs) by 9.9% after 48 h. The subsequent addition of L. casei led to a biphasic increase in TEER by 12.1% at 2 h followed by a decline at 6 h and the second peak of 86.7% increase was observed at 48 h. Another report by Ling et al. [51] demonstrated that the addition of Bifidobacterium cells along with LPS to Caco-2 monolayers significantly inhibited the reduction in TEER values as compared to LPS-treated monolayers. Further, the addition of L. plantarum DSM 2648 along with E. coli showed a 98.75% increase in TEER as compared to only E. coli-treated Caco-2 at 4 h followed by decline after 6 h [52]. Anderson et al. [53] showed that L. plantarum MB452 induced a 15–20% increase in TEER values of Caco-2 monolayers at 4 and 6 h as compared to untreated controls. Taken together these results indicate a valuable potential role for lactobacilli in protecting the gut and ameliorating epithelial cell damage.

Occludin is a 65 kDa integral plasma-membrane protein located in tight junctions that plays an important role in maintaining the barrier properties of tight junctions [54]. Whereas, E-cadherin is a calcium-dependent cell–cell adhesion glycoprotein that strengthens the cellular adhesion between the cells [55]. Therefore, we further studied the concentration of these proteins in LPS-treated Caco-2 cell lysates with or without the addition of L18 cells. LPS treatment of Caco-2 monolayers resulted in 1.9-fold and 1.8-fold reduction in the levels of occludin and E-cadherin proteins, respectively. The addition of L18 cells to LPS-treated Caco-2 monolayers increased the occludin and E-cadherin levels by 1.93-fold and 2.9-fold, respectively within 4 h. Thus, the observed increase in TEER values of Caco-2 monolayers upon addition of lactobacilli is possibly due to increased production of occludin and E-cadherin proteins that counteracted the LPS-mediated damage to the intestinal barrier. Similar results were demonstrated by another study, that showed that the addition of L. plantarum MB452 increased the mRNA levels of occludin by 1.36-fold [53]. Yang et al. [40] showed that the addition of L. reuteri cells to LPS-treated IPEC-J2 cells resulted in a twofold increase in mRNA levels of occludin. Karimi et al. [56] showed that the addition of L. reuteri cells to E. coli-treated IPEC-J2 cell monolayers caused 1.5- to twofold increase in E-cadherin levels. The mechanism through which L18 might enhance the levels of tight junction proteins could be related to its ability to secrete GABA. CS of GABA-secreting L. brevis was shown to increase the mRNA levels of tight junction proteins claudin and zona-occludin-1 and protect against IL-1beta-induced damage in a Caco-2 cell line [57]. In another study, purified GABA at concentration of 0.1–0.5 mM significantly increased the TEER levels indicating increased integrity of intestinal cell line Caco-2 [58]. GABA receptors are present on the intestinal cell lines and in response to binding GABA, the intestinal cells produce anti-inflammatory cytokines such as TGF-β and IL-10 and the production of proinflammatory cytokines is inhibited [59].

In vitro batch modeling of the digestive tract is used for evaluating the effects of potential probiotic and prebiotic substrates on fecal microbiota [60]. In this model, the microbiota from the stool samples of healthy humans is cultivated under simulated physiological conditions of the gut. Batch fermentation model to study the effect of Li. fermentum L18 on the composition of human fecal microbiome revealed that the addition of L18 had no effects on the alpha and beta diversities of the microbiome but differences in the relative abundance at the family level were observed. According to amplicon sequencing, after 24 h of fermentation, Proteobacteria dominated the microbiota followed by Firmicutes in both the samples; however, the increase in the L18-treated group was less as compared to untreated control. Proteobacteria is a phylum consisting of Gram-negative bacteria that includes members of Enterobacteriaceae family. Both CFU counts and 16 rRNA gene sequencing results have shown decrease in the counts of Enterobacteriaceae, which may account for less increase in Proteobacteria in lactobacilli-treated samples. The percentage of beneficial bacteria belonging to the families Bifidobacteriaceae and Lactobacillaceae increased by 1% and 18.4%, respectively in the L18-treated samples; whereas, they both decreased (by 0.6% and 0.94%, respectively) in the untreated sample. Increase in the Bifidobacteria was observed by both plating and 16S rRNA sequencing methods that indicate that L18 may be producing bifidogenic factors that promotes the growth of Bifidobacteria. In case of lactobacilli, although no differences in the counts between the groups was observed by the plating method but 16S rRNA sequencing showed that the relative abundance increased from 3% at 0 h to 18.45% at 24 h in L18 group. This may indicate that the added lactobacilli promoted the growth of unculturable species of lactobacilli which were unable to grow on MRS media. Similar to our results, Liu et al. [61] demonstrated that the addition of L. acidophilus (5 × 108 CFU) to fecal microbiota in batch fermentation resulted in a significant increase by almost 1 log10 CFU in both Bifidobacterium and Lactobacillus after 24 h. Ogué-Bon et al. [62] studied the effect of L. acidophilus 14 150B on the canine fecal microbiota by FISH analysis. The addition of L. acidophilus (109 cells) significantly increased the numbers of Bifidobacterium and Lactobacillus after 10 h of fermentation but after 24 h the number of Bifidobacterium decreased, whereas Lactobacillus numbers were higher as compared to the control. Further contrary to our study, the numbers of both Clostridia and Escherichia coli numbers increased after 24 h in the L. acidophilus group.

These results indicate that Li. fermentum L18 has several beneficial properties such as the ability to secrete high concentrations of GABA and to strengthen the intestinal gut barrier. It has the potential to be used as a psychobiotic or used commercially to produce GABA and GABA-enriched functional foods. L18 supplementation also positively modulated the microbiota of stool samples by increasing the abundance of beneficial gut microbes such as Lactobacillus spp. and Bifidobacterium and reducing the numbers of Enterococcus and Streptococcus spp. Further studies are required to determine the in vivo effects of L18 on the permeability and protection of the intestinal epithelium and to evaluate its immunomodulatory properties that could contribute to overall health of the host.

Conclusion

Our results showed that GABA producing Li. fermentum L18 has potential to strengthen the gut barrier by upregulating the production of junction proteins. L18 also modulates the fecal microbiota by increasing the abundance of beneficial micro-organisms. Therefore, L18 can be explored as psychobiotic or can be used to form GABA-enriched functional foods.

Availability of data and materials

Not applicable.

Abbreviations

GABA:

γ-Aminobutyric acid

TEER:

Transepithelial Electrical Resistance

LPS:

Lipopolysaccharide

CS:

Culture supernatant

MSG:

Monosodium glutamate

DMEM:

Dulbecco’s Modified Eagle Medium

PBS:

Phosphate-buffered saline

CFU:

Colony forming units

OTU:

Operational Taxonomic Units

PCoA:

Principal Coordinate Axis

References

  1. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191.

    PubMed  Google Scholar 

  2. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014;4: e005047.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Appanna VD, Appanna VD. Dysbiosis, probiotics, and prebiotics: in diseases and health. Human Microbes-The Power Within: Health, Healing and Beyond. 2018;8:81–122.

    Article  Google Scholar 

  4. Basson AR, Zhou Y, Seo B, Rodriguez-Palacios A, Cominelli F. Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res. 2020;226:1–11.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Health Organization (WHO W, others. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, a joint FAO/WHO expert consultation. Cordoba, Argentina, 1–4 October 2001. http://www.who.int/foodsafety/publications/fs_management/probiotics/en/index.html. 2002;

  6. Schepper JD, Collins FL, Rios-Arce ND, Raehtz S, Schaefer L, Gardinier JD, et al. Probiotic Lactobacillus reuteri prevents postantibiotic bone loss by reducing intestinal dysbiosis and preventing barrier disruption. J Bone Miner Res. 2019;34:681–98.

    Article  CAS  PubMed  Google Scholar 

  7. Luigi B, Andrea A, Leonardo F, Donato I, Luigi P, Salvo EA, et al. Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01). Acta Bio Medica: Atenei Parmensis. 2019;90:18.

    Google Scholar 

  8. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769–76.

    Article  CAS  PubMed  Google Scholar 

  9. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22:1137–50.

    Article  PubMed  Google Scholar 

  10. Maurano F, Mazzarella G, Luongo D, Stefanile R, D’arienzo R, Rossi M, et al. Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia. 2005;48:931–7.

    Article  CAS  PubMed  Google Scholar 

  11. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives: a possible etiologic factor. Ann Intern Med. 1986;105:883–5.

    Article  CAS  PubMed  Google Scholar 

  12. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology. 1993;104:1627–32.

    Article  CAS  PubMed  Google Scholar 

  13. Montalto M, Cuoco L, Ricci R, Maggiano N, Vecchio FM, Gasbarrini G. Immunohistochemical analysis of ZO-1 in the duodenal mucosa of patients with untreated and treated celiac disease. Digestion. 2002;65:227–33.

    Article  CAS  PubMed  Google Scholar 

  14. Schulzke J-D, Bentzel CJ, Schulzke I, Riecken E-O, Fromm M. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res. 1998;43:435–41.

    Article  CAS  PubMed  Google Scholar 

  15. Fasano A, Nataro JP. Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins. Adv Drug Deliv Rev. 2004;56:795–807.

    Article  CAS  PubMed  Google Scholar 

  16. Hernandez-Valdes JA, Stegge M, Hermans J, Teunis J, van Tatenhove-Pel RJ, Teusink B, et al. Enhancement of amino acid production and secretion by Lactococcus lactis using a droplet-based biosensing and selection system. Metab Eng Commun. 2020;11:e00133.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kahouli I, Malhotra M, Tomaro-Duchesneau C, Saha S, Marinescu D, Rodes LS, et al. Screening and in-vitro analysis of Lactobacillus reuteri strains for short chain fatty acids production, stability and therapeutic potentials in colorectal cancer. J Bioequivalence Bioavailab. 2015;7:39.

    CAS  Google Scholar 

  18. Cataldo PG, Villegas JM, de Giori GS, Saavedra L, Hebert EM. Enhancement of γ-aminobutyric acid (GABA) production by Lactobacillus brevis CRL 2013 based on carbohydrate fermentation. Int J Food Microbiol. 2020;333: 108792.

    Article  CAS  PubMed  Google Scholar 

  19. Angelin J, Kavitha M. Exopolysaccharides from probiotic bacteria and their health potential. Int J Biol Macromol. 2020;162:853–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28:405–40.

    Article  CAS  PubMed  Google Scholar 

  21. Adeghate E, Ponery AS. GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats. Tissue Cell. 2002;34:1–6.

    Article  CAS  PubMed  Google Scholar 

  22. Boonstra E, De Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015;8:1520.

    Google Scholar 

  23. Sharon G, Garg N, Debelius J, Knight R, Dorrestein PC, Mazmanian SK. Specialized metabolites from the microbiome in health and disease. Cell Metab. 2014;20:719–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lim HS, Seo D-H, Cha I-T, Lee H, Nam Y-D, Seo M-J. Expression and characterization of glutamate decarboxylase from Lactobacillus brevis HYE1 isolated from kimchi. World J Microbiol Biotechnol. 2018;34:1–10.

    Article  CAS  Google Scholar 

  25. Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res. 2015;93:11–21.

    Article  CAS  PubMed  Google Scholar 

  26. Kim JA, Park MS, Kang SA, Ji GE. Production of γ-aminobutyric acid during fermentation of Gastrodia elata Bl. by co-culture of Lactobacillus brevis GABA 100 with Bifidobacterium bifidum BGN4. Food Sci Biotechnol. 2014;23:459–66.

    Article  CAS  Google Scholar 

  27. Hagiwara H, Seki T, Ariga T. The effect of pre-germinated brown rice intake on blood glucose and PAI-1 levels in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem. 2004;68:444–7.

    Article  CAS  PubMed  Google Scholar 

  28. Hepsomali P, Groeger JA, Nishihira J, Scholey A. Effects of oral gamma-aminobutyric acid (GABA) administration on stress and sleep in humans: A systematic review. Front Neurosci. 2020;14:923.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hosseini Dastgerdi A, Sharifi M, Soltani N. GABA administration improves liver function and insulin resistance in offspring of type 2 diabetic rats. Sci Rep. 2021;11:23155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schuller HM, Al-Wadei HAN, Majidi M. Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis. 2008;29:1979–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhang Q, Zeng L, Tan X, Tang J, Xiang W. An efficient γ-aminobutyric acid (GABA) producing and nitrite reducing ability of Lactobacillus plantarum BC114 isolated from Chinese Paocai. Food Sci Technol Res. 2017;23:749–55.

    Article  CAS  Google Scholar 

  32. Park S-Y, Lee J-W, Lim S-D. The probiotic characteristics and GABA production of Lactobacillus plantarum K154 isolated from kimchi. Food Sci Biotechnol. 2014;23:1951–7.

    Article  CAS  Google Scholar 

  33. Wu C-H, Hsueh Y-H, Kuo J-M, Liu S-J. Characterization of a potential probiotic Lactobacillus brevis RK03 and efficient production of γ-aminobutyric acid in batch fermentation. Int J Mol Sci. 2018;19:143.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Komatsuzaki N, Shima J, Kawamoto S, Momose H, Kimura T. Production of γ-aminobutyric acid (GABA) by Lactobacillus paracasei isolated from traditional fermented foods. Food Microbiol. 2005;22:497–504.

    Article  CAS  Google Scholar 

  35. Kanehira T, Nakamura Y, Nakamura K, Horie K, Horie N, Furugori K, et al. Relieving occupational fatigue by consumption of a beverage containing γ-amino butyric acid. J Nutr Sci Vitaminol (Tokyo). 2011;57:9–15.

    Article  CAS  PubMed  Google Scholar 

  36. Cho YR, Chang JY, Chang HC. Production of gamma-aminobutyric acid (GABA) by Lactobacillus buchneri isolated from kimchi and its neuroprotective effect on neuronal cells. J Microbiol Biotechnol. 2007;17:104–9.

    CAS  PubMed  Google Scholar 

  37. Food, Administration D, others. Gamma-aminobutyric Acid GRAS Notice. 2008.

  38. Kaur S, Sharma P, Kalia N, Singh J, Kaur S. Anti-biofilm properties of the fecal probiotic lactobacilli against Vibrio spp. Front Cell Infect Microbiol. 2018;8:120.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Tennant JR. Evaluation of the trypan blue technique for determination of cell viability. Transplantation. 1964;2:685–94.

    Article  CAS  PubMed  Google Scholar 

  40. Yang F, Wang A, Zeng X, Hou C, Liu H, Qiao S. Lactobacillus reuteri I5007 modulates tight junction protein expression in IPEC-J2 cells with LPS stimulation and in newborn piglets under normal conditions. BMC Microbiol. 2015;15:1–11.

    Article  Google Scholar 

  41. Parmanand BA, Kellingray L, Le Gall G, Basit AW, Fairweather-Tait S, Narbad A. A decrease in iron availability to human gut microbiome reduces the growth of potentially pathogenic gut bacteria; an in vitro colonic fermentation study. J Nutr Biochem. 2019;67:20–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yu L, Duan H, Kellingray L, Cen S, Tian F, Zhao J, et al. Lactobacillus plantarum-mediated regulation of dietary aluminum induces changes in the human gut microbiota: an in vitro colonic fermentation study. Probiotics Antimicrob Proteins. 2021;13:398–412.

    Article  CAS  PubMed  Google Scholar 

  43. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome. 2018;6:1–17.

    Article  Google Scholar 

  44. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015;26:27663.

    PubMed  Google Scholar 

  46. Dhakal R, Bajpai VK, Baek K-H. Production of GABA (γ-aminobutyric acid) by microorganisms: a review. Braz J Microbiol. 2012;43:1230–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Li H, Qiu T, Gao D, Cao Y. Medium optimization for production of gamma-aminobutyric acid by Lactobacillus brevis NCL912. Amino Acids. 2010;38:1439–45.

    Article  CAS  PubMed  Google Scholar 

  48. Ting Wong CG, Bottiglieri T, Snead OC III. Gaba, γ-hydroxybutyric acid, and neurological disease. Ann Neurol. 2003;54:S3–12.

    Article  Google Scholar 

  49. Nighot M, Al-Sadi R, Guo S, Rawat M, Nighot P, Watterson MD, et al. Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4/myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression. Am J Pathol. 2017;187:2698–710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fang H-W, Fang S-B, Chiang Chiau J-S, Yeung C-Y, Chan W-T, Jiang C-B, et al. Inhibitory effects of Lactobacillus casei subsp. rhamnosus on Salmonella lipopolysaccharide-induced inflammation and epithelial barrier dysfunction in a co-culture model using Caco-2/peripheral blood mononuclear cells. J Med Microbiol. 2010;59:573–9.

    Article  CAS  PubMed  Google Scholar 

  51. Ling X, Linglong P, Weixia D, Hong W. Protective effects of Bifidobacterium on intestinal barrier function in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. PLoS ONE. 2016;11: e0161635.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Anderson RC, Cookson AL, McNabb WC, Kelly WJ, Roy NC. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol Lett. 2010;309:184–92.

    CAS  PubMed  Google Scholar 

  53. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol. 2010;10:1–11.

    Article  Google Scholar 

  54. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005;57:883–917.

    Article  CAS  PubMed  Google Scholar 

  55. den Bossche J, Malissen B, Mantovani A, De Baetselier P, Van Ginderachter JA. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood J Am Soc Hematol. 2012;119:1623–33.

    Google Scholar 

  56. Karimi S, Jonsson H, Lundh T, Roos S. Lactobacillus reuteri strains protect epithelial barrier integrity of IPEC-J2 monolayers from the detrimental effect of enterotoxigenic Escherichia coli. Physiol Rep. 2018;6: e13514.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Sokovic Bajic S, Djokic J, Dinic M, Veljovic K, Golic N, Mihajlovic S, et al. GABA-producing natural dairy isolate from artisanal zlatar cheese attenuates gut inflammation and strengthens gut epithelial barrier in vitro. Front Microbiol. 2019;10:527.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Long TW. Effects of GABA on inflammation and intestinal barrier disruption. 2022;

  59. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci. 2010;107:2580–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Macfarlane GT, Macfarlane S. Models for intestinal fermentation: association between food components, delivery systems, bioavailability and functional interactions in the gut. Curr Opin Biotechnol. 2007;18:156–62.

    Article  CAS  PubMed  Google Scholar 

  61. Liu Y, Gibson GR, Walton GE. An in vitro approach to study effects of prebiotics and probiotics on the faecal microbiota and selected immune parameters relevant to the elderly. PLoS ONE. 2016;11: e0162604.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ogué-Bon E, Khoo C, Hoyles L, McCartney AL, Gibson GR, Rastall RA. In vitro fermentation of rice bran combined with Lactobacillus acidophilus 14 150B or Bifidobacterium longum 05 by the canine faecal microbiota. FEMS Microbiol Ecol. 2011;75:365–76.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would especially like to thank Bhavika A Parmanand for helping in setting up batch fermentation experiments and Henry Whiley for DNA extraction.

Funding

This work was supported by the UK Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programmes Gut Microbes and Health (BB/R012490/1 Theme 3 BBS/E/F/000PR10356), Food Microbiome and Health (BB/X011054/1 Theme 4 BBS/E/F/000PR13633) and by research grant (Grant Number: 42-478/2013 SR) sponsored by University Grants Commission (UGC), New Delhi, India.

Author information

Author notes

  1. Sumanpreet Kaur

    Present address: Department of Medical Laboratory Sciences, Lovely Professional University, Jalandhar, India

  2. Saskia Neuert

    Present address: East Genomics Laboratory Hub, Cambridge University Hospitals Genomic Laboratory, Hills Road, Cambridge, UK

Authors and Affiliations

  1. Department of Microbiology, Guru Nanak Dev University, Amritsar, India

    Sumanpreet Kaur, Preeti Sharma & Sukhraj Kaur

  2. Gut Microbes and Health Institute Strategic Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK

    Sumanpreet Kaur, Melinda J. Mayer, Saskia Neuert & Arjan Narbad

Authors
  1. Sumanpreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Preeti Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melinda J. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saskia Neuert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arjan Narbad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sukhraj Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SK and AN conceptualized and designed the whole study. SPK performed all the experiments, MJM planned the experiments with cell lines and batch fermentation. SN analyzed the amplicon sequencing data of microbiome in batch fermentation. SK and SPK wrote the manuscript. PS helped with statistical analysis of the data. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sukhraj Kaur.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the UK research ethics committee (REC15/LO/2169). The informed consent of all the participating subjects was obtained.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

The species name and GenBank accession numbers of fecal lactobacilli isolates used in the study.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaur, S., Sharma, P., Mayer, M.J. et al. Beneficial effects of GABA-producing potential probiotic Limosilactobacillus fermentum L18 of human origin on intestinal permeability and human gut microbiota. Microb Cell Fact 22, 256 (2023). https://doi.org/10.1186/s12934-023-02264-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12934-023-02264-2

Keywords

Microbial Cell Factories

ISSN: 1475-2859

Contact us